Pending EO 12866 Regulatory Review

RIN: 0910-ZB96         Received Date: 04/10/2024 
Title: Diversity Action Plans to Improve Enrollment of Participants from Underrepresented Populations in Clinical Studies; Guidance for Industry 
Agency/Subagency: HHS / FDA   Stage: Notice 
Legal Deadline: None  Section 3(f)(1) Significant: No 
International Impacts: No Affordable Care Act [Pub. L. 111-148 & 111-152]: No
Pandemic Response: No Dodd-Frank Wall Street Reform and Consumer Protection Act, [Pub. L. 111-203]: No